"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 3 | 4 |
| 1995 | 1 | 2 | 3 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 4 | 3 | 7 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 5 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 5 | 2 | 7 |
| 2011 | 6 | 1 | 7 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 3 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 4 | 6 |
| 2020 | 5 | 3 | 8 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Treatment of Trichilemmomas With Topical Sirolimus. JAMA Dermatol. 2023 03 01; 159(3):340-342.
-
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
-
Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort. J Pediatr Hematol Oncol. 2022 10 01; 44(7):383-387.
-
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
-
Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene. 2021 Aug; 40(31):5002-5012.
-
Guarding against nonmelanoma skin cancer in solid organ transplant recipients. J Fam Pract. 2021 04; 70(3):121-130.
-
Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation. 2021 02 01; 105(2):436-442.
-
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2021 01; 8(1).
-
Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Int J Rheum Dis. 2021 Jan; 24(1):120-124.
-
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.